NurExone Biologic: The Q2 2026 Financials, and What They Set

The quarter, in plain language

Reporting quarters at preclinical-stage biotechs matter less for the current-period P&L and more for what the operational activity around them signals about the pace of the underlying development program. NurExone's Q2 2026 print carried more than usual on that second dimension.

On the manufacturing side, on August 12, 2026 the company disclosed that its U.S. subsidiary Exo-Top Inc. and NurExone had signed a binding memorandum of understanding with Made Scientific, Inc. to establish exclusive U.S. Good Manufacturing Practice (GMP) manufacturing and commercial exosome supply for NurExone's bone-marrow-derived exosomes. Technical documentation transfer has commenced, and the parties are targeting initial GMP exosome batches in the first half of 2027. The MOU is binding, but a definitive agreement has not yet been signed.

On the commercial side, on June 24, 2026 subsidiary Exo-Top Inc. entered into a binding MOU with ExoLyra LLC setting out principal commercial terms for a proposed distribution agreement in Mexico. The proposed structure includes exclusive rights to market, import, and sell specified naïve MSC-derived exosome products in Mexico for an initial three-year term, supported by a US$180,000 territorial exclusivity fee and minimum purchase commitments. This is the first meaningful commercial arrangement in NurExone's naïve exosome distribution channel.

On the science side, on August 14, 2026 the company reported results showing statistically significant higher numbers of myelin-positive cells in ExoPTEN-treated spinal-cord-injury animal models compared with controls. Myelin is the insulating sheath around nerve fibres; its regrowth after spinal cord injury is one of the specific biological signals researchers look for as evidence of nerve regeneration.

The numbers

Q2 2026 operating expenses trended favourably versus the same quarter in 2025. Research and development expenses, net were US$0.75 million (Q2 2026) versus US$0.70 million (Q2 2025). The modest increase reflected higher material purchases and development activity around ExoPTEN. General and administrative expenses were US$0.93 million (Q2 2026) versus US$1.13 million (Q2 2025). The decrease was primarily reductions in professional services and legal costs, partially offset by share-based compensation. Net loss was US$1.68 million (Q2 2026) versus US$1.85 million (Q2 2025). CFO Eran Ovadya framed the quarter's spending as "in line with plan" and noted that proceeds from a non-brokered private placement closed on June 26, 2026 (approximately US$441,000 in gross proceeds) and a subsequent non-brokered private placement closed on August 20, 2026 (approximately US$762,000 in gross proceeds) provide additional working capital to support ExoPTEN development. Both placements were priced in units and resulted in additional share issuance.

What the quarter set up

For a preclinical biotech whose principal near-term regulatory objective is an Investigational New Drug (IND) submission in the first half of 2027, the Q2 2026 print did three things that materially move the shape of that path.

First, it put a credentialed U.S. GMP manufacturing partner behind the program. Prior to August 12, NurExone had preclinical data and regulatory designations but had not disclosed a specific U.S. GMP manufacturing partner at the scale required for a clinical program. The Made Scientific MOU addresses that.

Second, it opened NurExone's first meaningful commercial distribution channel for the naïve exosome business through ExoTop. The ExoLyra Mexico MOU is small in absolute dollars but it establishes the commercial framework the company may be able to extend to other jurisdictions over time.

Third, it added another data point to the preclinical evidence base. Statistically significant increases in myelin-positive cells in treated versus control animal models is precisely the kind of specific biological signal an IND package needs to include.

What comes next

The near-term markers on NurExone's calendar are concrete. First, execution of a definitive agreement with Made Scientific within the six-month MOU window. Second, initiation of first GMP exosome batches in H1 2027. Third, the IND submission itself in H1 2027. Fourth, the shareholder vote on the proposed share consolidation at the September 15, 2026 annual general meeting. And fifth, continued preclinical data readouts, particularly from the large-scale optic nerve study at Sheba Medical Center.

NurExone remains a preclinical-stage biotech. The vast majority of preclinical drug candidates never reach regulatory approval, and any of the milestones above can slip. But the Q2 2026 print was the quarter where the manufacturing side of the story stopped being an open question, and that changes the shape of what comes next.

The tickers are NRX on the TSX Venture Exchange, NRXBF on the U.S. OTCQB, and J90 on the Frankfurt Stock Exchange. For additional information, visit nurexone.com or public filings on SEDAR+.

Disclaimer: This content has been paid for by NurExone Biologic Inc. Cashu Group was compensated by NurExone Biologic Inc. for the creation and distribution of this content. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. All financial figures, scientific claims, pipeline details, and company data referenced come from NurExone Biologic Inc.'s public disclosures, press releases, and SEDAR+ filings. Preclinical results referenced are from animal studies and do not guarantee similar outcomes in humans. Orphan Drug Designations referenced provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. The Made Scientific memorandum of understanding referenced is a binding MOU, not a completed definitive agreement; if the parties do not execute a definitive agreement within six months of MOU execution, the MOU and its exclusivity obligations automatically terminate. The ExoLyra memorandum of understanding referenced is a binding MOU for a proposed distribution agreement; a definitive distribution agreement has not yet been signed. Private placements completed in June and August 2026 resulted in additional share issuance and dilution to existing shareholders. References to other companies in the spinal cord injury and exosome therapeutics pipelines (including NervGen Pharma Inc., Lineage Cell Therapeutics, Aegle Therapeutics, and Capricor Therapeutics) are descriptive of the competitive landscape and are not comparisons implying equivalent clinical or commercial outcomes for NurExone. References to prior work by team members at other companies are historical and are not an indication of future performance at NurExone Biologic. The ExoTop naïve exosome commercial business is at an early stage and no anticipated revenue level is guaranteed; commercial arrangements referenced (including the ExoLyra Mexico MOU) may not produce anticipated revenues on the timelines currently disclosed. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory approval. Readers should conduct their own due diligence, consult NurExone's public filings on SEDAR+, and consult with a qualified financial advisor before making any investment decisions.